Skip header and navigation

2 records – page 1 of 1.

Chlamydia trachomatis cervical infection: prevalence and determinants among women presenting for routine gynecologic examination.

https://arctichealth.org/en/permalink/ahliterature225543
Source
CMAJ. 1991 Oct 15;145(8):953-61
Publication Type
Article
Date
Oct-15-1991
Author
R. Massé
H. Laperrière
H. Rousseau
J. Lefebvre
R S Remis
Author Affiliation
Department of Epidemiology and Biostatistics, McGill University, Montreal, Que.
Source
CMAJ. 1991 Oct 15;145(8):953-61
Date
Oct-15-1991
Language
English
Publication Type
Article
Keywords
Adolescent
Adult
Age Factors
Chlamydia Infections - diagnosis - epidemiology
Chlamydia trachomatis - isolation & purification
False Positive Reactions
Female
Humans
Middle Aged
Papanicolaou test
Prevalence
Prospective Studies
Quebec - epidemiology
Regression Analysis
Risk factors
Sexual Behavior
Urban health
Uterine Cervicitis - diagnosis - epidemiology - microbiology
Vaginal Smears
Abstract
To determine the prevalence of and risk indicators for Chlamydia trachomatis cervical infection among women presenting for a periodic medical examination.
Prevalence study.
Centre local de services communautaires (CLSC) Saint-Louis du Parc, Montreal.
All women presenting for a routine gynecologic examination from May 1985 to July 1986. Of the 773 (99%) who agreed to participate 56 were excluded because of inadequate diagnostic tests (34), antibiotic intake in the preceding 6 weeks (19) or loss to follow-up after the initial visit (3).
Culture was the diagnostic standard, but rapid diagnostic tests were also used. From the identified cases logistic regression analysis was used to evaluate the following risk indicators: age, place of residence, use of oral contraceptives, sexual partners and frequency, history of sexually transmitted disease (STD) and abnormalities found on genital examination.
Fifty-one of the women were found to have C. trachomatis infection, for a prevalence rate of 7.1%; 32 (63%) were completely asymptomatic. Three independent indicators were found: age of 25 years or less (odds ratio [OR] 3.2, 95% confidence limits [CL] 1.8 and 5.9), cervical erythema, contact bleeding or mucopurulent exudate (OR 2.5, 95% CL 1.4 and 4.5) and residency in the CLSC area (OR 2.3, 95% CL 1.1 and 5.1). A history of STD or vaginitis had a significant protective effect in women 30 years of age or more (OR 0.2).
Case-finding for chlamydial infection could be an effective public health measure among women 25 years of age or less and among those with signs of cervicitis when they present for a Papanicolaou test.
Notes
Cites: Sex Transm Dis. 1978 Apr-Jun;5(2):51-610328031
Cites: CMAJ. 1989 Feb 1;140(3):297-3012914240
Cites: CMAJ. 1987 Jul 1;137(1):33-73594332
Cites: JAMA. 1986 Sep 5;256(9):1178-93016356
Cites: JAMA. 1988 Jul 8;260(2):207-133133496
Cites: Obstet Gynecol. 1988 Jan;71(1):101-83122137
Cites: Ann Intern Med. 1986 Aug;105(2):189-963089086
Cites: JAMA. 1986 Apr 4;255(13):1730-43081742
Cites: J Clin Microbiol. 1988 Apr;26(4):726-313284899
Cites: Sex Transm Dis. 1989 Jan-Mar;16(1):21-72667152
Cites: N Engl J Med. 1989 Mar 23;320(12):802-42922028
Cites: Ann Intern Med. 1988 May;108(5):710-73282465
Cites: Am J Epidemiol. 1988 Aug;128(2):298-3083394697
Cites: Ann Intern Med. 1987 Aug;107(2):188-943300458
Cites: J Infect Dis. 1986 Jul;154(1):141-83519787
Cites: Fam Plann Perspect. 1987 Nov-Dec;19(6):252-63436412
Cites: J Am Coll Health. 1987 Jul;36(1):39-433624655
Cites: JAMA. 1987 Apr 17;257(15):2073-43560384
Cites: JAMA. 1987 Apr 17;257(15):2070-23560383
Cites: JAMA. 1986 Jun 27;255(24):3374-73712696
Cites: Annu Rev Public Health. 1985;6:85-1063873248
Cites: Can Med Assoc J. 1985 Jul 1;133(1):34-54039970
Cites: JAMA. 1985 Apr 19;253(15):2246-503974117
Cites: Am J Epidemiol. 1985 Jan;121(1):107-153964985
Cites: N Engl J Med. 1984 Jul 5;311(1):1-66427611
Cites: Epidemiol Rev. 1983;5:96-1236357824
Cites: Pediatrics. 1984 Jun;73(6):836-406547226
Cites: J Pediatr. 1984 Jan;104(1):141-66546309
Cites: Am J Clin Pathol. 1983 Dec;80(6):844-96688921
Cites: West J Med. 1983 Mar;138(3):375-96858125
Cites: Am J Clin Pathol. 1983 Apr;79(4):421-56837510
Cites: Br J Vener Dis. 1981 Aug;57(4):259-626791761
Cites: Union Med Can. 1982 Oct;111(10):856-61, 865-77179581
Cites: Can Med Assoc J. 1982 Nov 15;127(10):974-67139448
Cites: J Pediatr. 1981 Jun;98(6):981-57229806
Cites: Br J Vener Dis. 1979 Dec;55(6):415-8526844
Cites: Am J Epidemiol. 1978 Jan;107(1):71-6623091
PubMed ID
1913429 View in PubMed
Less detail

A 1-year evaluation of Syva MicroTrak Chlamydia enzyme immunoassay with selective confirmation by direct fluorescent-antibody assay in a high-volume laboratory.

https://arctichealth.org/en/permalink/ahliterature217461
Source
J Clin Microbiol. 1994 Sep;32(9):2208-11
Publication Type
Article
Date
Sep-1994
Author
E L Chan
K. Brandt
G B Horsman
Author Affiliation
Laboratory and Disease Control Services, Saskatchewan Health, Regina, Canada.
Source
J Clin Microbiol. 1994 Sep;32(9):2208-11
Date
Sep-1994
Language
English
Publication Type
Article
Keywords
Algorithms
Chlamydia Infections - diagnosis - epidemiology - microbiology
Chlamydia trachomatis - immunology - isolation & purification
Cost Control
Densitometry
Diagnostic Tests, Routine - economics
Evaluation Studies as Topic
Female
Fluorescent Antibody Technique - economics
Humans
Immunoenzyme Techniques - economics
Male
Predictive value of tests
Prevalence
Reagent kits, diagnostic
Saskatchewan - epidemiology
Seasons
Sensitivity and specificity
Urethritis - diagnosis - epidemiology - microbiology
Uterine Cervicitis - diagnosis - epidemiology - microbiology
Abstract
TThe Syva MicroTrak Chlamydia enzyme immunoassay (EIA; Syva Company, San Jose, Calif.) with cytospin and direct fluorescent-antibody assay (DFA) confirmation was evaluated on 43,630 urogenital specimens over a 1-year period in the Provincial Laboratory in Regina, Saskatchewan, Canada. This was a two-phase study intended to define a testing algorithm for Chlamydia trachomatis that would be both highly accurate and cost-effective in our high-volume (> 3,000 tests per month) laboratory. The prevalence of C. trachomatis infection in our population is moderate (8 to 9%). In phase 1, we tested 6,022 male and female urogenital specimens by EIA. All specimens with optical densities above the cutoff value and those within 30% below the cutoff value were retested by DFA. This was 648 specimens (10.8% of the total). A total of 100% (211 of 211) of the specimens with optical densities equal to or greater than 1.00 absorbance unit (AU) above the cutoff value, 98.2% (175 of 178) of the specimens with optical densities of between 0.500 and 0.999 AU above the cutoff value, and 83% (167 of 201) of the specimens with optical densities within 0.499 AU above the cutoff value were confirmed to be positive. A total of 12% (7 of 58) of the specimens with optical densities within 30% below the cutoff value were positive by DFA. In phase 2, we tested 37,608 specimens (32,495 from females; 5,113 from males) by EIA. Only those specimens with optical densities of between 0.499 AU above and 30% below the cutoff value required confirmation on the basis of data from phase 1 of the study. This was 4.5% of all specimens tested. This decrease in the proportion of specimens requiring confirmation provides a significant cost savings to the laboratory. The testing algorithm gives us a 1-day turnaround time to the final confirmed test results. The MicroTrak EIA performed very well in both phases of the study, with a sensitivity, specificity, positive predictive value, and negative predictive value of 96.1, 99.1, 90.3, and 99.7%, respectively, in phase 2. We suggest that for laboratories that use EIA for Chlamydia testing, a study such as this one will identify an appropriate optical density range for confirmatory testing for samples from that particular population.
Notes
Cites: Epidemiol Rev. 1983;5:96-1236357824
Cites: J Clin Microbiol. 1993 Jun;31(6):1646-78315010
Cites: Diagn Microbiol Infect Dis. 1992 Nov-Dec;15(8):663-81478048
Cites: J Clin Microbiol. 1990 Nov;28(11):2473-62254422
PubMed ID
7814548 View in PubMed
Less detail